Loading stock data…
GLPG
$28.00+0.17 (+0.61%)
Market ClosedLast close May 1
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Galapagos NV in the Healthcare sector is trading at $28.00. The stock is currently 26% below its 52-week high of $37.78, remaining 13.1% below its 200-day moving average. Technical signals show neutral RSI of 42 and bullish MACD crossover, explaining why GLPG maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 42) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.00
Potential Upside
218.8%
Whystock Fair Value$89.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and system...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.96B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.09
Beta
Defensive asset. Lower volatility than the S&P 500.
0.15
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-8.79%
Volume
Today's trading volume
107,016
Recent News
RBC Cuts Galapagos NV (GLPG) Price Target to $28, Maintains Sector Perform Ahead of Q1
We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Galapagos NV is among the most undervalued stocks to invest in. TheFly reported on April 7 that RBC Capital Markets adjusted its outlook on GLPG, reducing its price target from $33 to $28 while maintaining a Sector Perform rating. The […]
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets
Galapagos NV (NASDAQ:GLPG) is one of the 7 Fastest Growing European Stocks to Invest In. On March 31, 2026, Galapagos NV (NASDAQ:GLPG) announced a binding agreement with Gilead Sciences (NASDAQ:GILD) related to Gilead’s planned acquisition of Ouro Medicines, a U.S.-based biotech focused on T cell engager therapies for autoimmune diseases. The deal includes access to […]
Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials
Galapagos (NASDAQ:GLPG) said it has entered into a binding collaboration agreement with Gilead focused on Gamgertamig, a BCMA x CD3 T-cell engager being developed for autoimmune diseases. Chief Executive Officer Henry Gosebruch said the deal follows “advanced discussions” disclosed the prior week an
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration
Gilead Sciences (NasdaqGS:GILD) has entered a definitive agreement to acquire Ouro Medicines, expanding into T cell engager therapies for autoimmune diseases. The company has also signed a collaboration agreement with Galapagos NV to advance T cell engager therapies. These moves affect Gilead's research pipeline and potential future treatment offerings. Gilead Sciences, trading at $136.34, has seen a 12.1% return year to date and a 24.9% return over the past year. Over 3 years, the stock...
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 23, The Wall Street Journal reported that Gilead Sciences, Inc. (NASDAQ:GILD) plans to acquire Ouro Medicines, a developer of autoimmune-disease therapies, for up to about $2.18 billion. The company also intends to develop the acquired […]